$REGN
Regeneron Pharmaceuticals Inc

2014 Q2 Form 10-Q Financial Statement

#000153217614000035 Filed on August 05, 2014

View on sec.gov

Income Statement

Concept 2014 Q2 2013 Q2
Revenue $665.7M $457.6M
YoY Change 45.46% 50.34%
Cost Of Revenue $29.95M $27.28M
YoY Change 9.76% 24.91%
Gross Profit $635.8M $430.4M
YoY Change 47.73% 52.31%
Gross Profit Margin 95.5% 94.04%
Selling, General & Admin $96.73M $72.46M
YoY Change 33.49% 51.9%
% of Gross Profit 15.21% 16.84%
Research & Development $294.5M $187.5M
YoY Change 57.1% 27.2%
% of Gross Profit 46.32% 43.56%
Depreciation & Amortization $13.00M $9.700M
YoY Change 34.02% 3.19%
% of Gross Profit 2.04% 2.25%
Operating Expenses $391.2M $259.9M
YoY Change 50.52% 33.24%
Operating Profit $228.1M $158.1M
YoY Change 44.27% 80.73%
Interest Expense $10.18M $11.37M
YoY Change -10.45% 1.15%
% of Operating Profit 4.46% 7.19%
Other Income/Expense, Net -$19.29M -$10.41M
YoY Change 85.26% -3.02%
Pretax Income $208.8M $147.7M
YoY Change 41.38% 92.45%
Income Tax $112.5M $60.32M
% Of Pretax Income 53.86% 40.84%
Net Earnings $96.35M $87.38M
YoY Change 10.27% 13.86%
Net Earnings / Revenue 14.47% 19.09%
Basic Earnings Per Share $0.96 $0.89
Diluted Earnings Per Share $0.85 $0.79
COMMON SHARES
Basic Shares Outstanding 100.4M shares 97.70M shares
Diluted Shares Outstanding 113.0M shares 111.1M shares

Balance Sheet

Concept 2014 Q2 2013 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $817.0M $538.0M
YoY Change 51.86% 78.74%
Cash & Equivalents $600.1M $381.7M
Short-Term Investments $217.0M $156.0M
Other Short-Term Assets $126.0M $98.00M
YoY Change 28.57% 1125.0%
Inventory $109.9M $57.16M
Prepaid Expenses
Receivables $664.1M $767.9M
Other Receivables $0.00 $0.00
Total Short-Term Assets $1.919B $1.561B
YoY Change 22.89% 103.04%
LONG-TERM ASSETS
Property, Plant & Equipment $707.3M $419.7M
YoY Change 68.55% 12.81%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $551.0M $173.0M
YoY Change 218.5% -39.93%
Other Assets $8.877M $15.21M
YoY Change -41.64% -45.68%
Total Long-Term Assets $1.537B $816.9M
YoY Change 88.2% 18.56%
TOTAL ASSETS
Total Short-Term Assets $1.919B $1.561B
Total Long-Term Assets $1.537B $816.9M
Total Assets $3.456B $2.378B
YoY Change 45.32% 63.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $47.00M $24.00M
YoY Change 95.83% -7.69%
Accrued Expenses $236.0M $129.0M
YoY Change 82.95% 27.72%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $351.6M $203.8M
YoY Change 72.51% 11.37%
LONG-TERM LIABILITIES
Long-Term Debt $517.0M $473.0M
YoY Change 9.3% 6.29%
Other Long-Term Liabilities $14.97M $10.20M
YoY Change 46.75% -95.66%
Total Long-Term Liabilities $14.97M $10.20M
YoY Change 46.75% -98.5%
TOTAL LIABILITIES
Total Short-Term Liabilities $351.6M $203.8M
Total Long-Term Liabilities $14.97M $10.20M
Total Liabilities $1.087B $884.9M
YoY Change 22.86% 2.54%
SHAREHOLDERS EQUITY
Retained Earnings $65.49M -$330.8M
YoY Change -119.8%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost) -$43.85M
YoY Change
Treasury Stock Shares 521.9K shares
Shareholders Equity $2.369B $1.493B
YoY Change
Total Liabilities & Shareholders Equity $3.456B $2.378B
YoY Change 45.32% 63.12%

Cashflow Statement

Concept 2014 Q2 2013 Q2
OPERATING ACTIVITIES
Net Income $96.35M $87.38M
YoY Change 10.27% 13.86%
Depreciation, Depletion And Amortization $13.00M $9.700M
YoY Change 34.02% 3.19%
Cash From Operating Activities $336.4M $128.2M
YoY Change 162.4% -263.52%
INVESTING ACTIVITIES
Capital Expenditures -$70.90M -$34.50M
YoY Change 105.51% 169.53%
Acquisitions
YoY Change
Other Investing Activities -$47.30M $151.1M
YoY Change -131.3% -219.64%
Cash From Investing Activities -$118.2M $116.6M
YoY Change -201.37% -183.76%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -80.10M -43.50M
YoY Change 84.14% 770.0%
NET CHANGE
Cash From Operating Activities 336.4M 128.2M
Cash From Investing Activities -118.2M 116.6M
Cash From Financing Activities -80.10M -43.50M
Net Change In Cash 138.1M 201.3M
YoY Change -31.4% -190.43%
FREE CASH FLOW
Cash From Operating Activities $336.4M $128.2M
Capital Expenditures -$70.90M -$34.50M
Free Cash Flow $407.3M $162.7M
YoY Change 150.34% -348.02%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q2 us-gaap Accounts And Notes Receivable Net
AccountsAndNotesReceivableNet
112984000 USD
CY2013Q4 us-gaap Accounts And Notes Receivable Net
AccountsAndNotesReceivableNet
63189000 USD
CY2014Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
283385000 USD
CY2013Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
250896000 USD
CY2013Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
61936000 USD
CY2014Q2 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
47231000 USD
CY2014Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
664075000 USD
CY2013Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
787071000 USD
us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.00
us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.060
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
CY2013Q4 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
104707000 USD
CY2014Q2 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
116865000 USD
CY2014Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
4263000 USD
CY2013Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1188000 USD
CY2014Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2342839000 USD
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2045857000 USD
us-gaap Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net
AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
244197000 USD
us-gaap Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net
AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
7876000 USD
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
73137000 USD
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
64990000 USD
us-gaap Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments
-156651000 USD
us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
-143041000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
155137000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
98728000 USD
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
223139000 USD
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
28162000 USD
CY2014Q2 us-gaap Assets
Assets
3456078000 USD
CY2013Q4 us-gaap Assets
Assets
2951013000 USD
CY2014Q2 us-gaap Assets Current
AssetsCurrent
1918695000 USD
CY2013Q4 us-gaap Assets Current
AssetsCurrent
1796934000 USD
CY2014Q2 us-gaap Available For Sale Securities
AvailableForSaleSecurities
767592000 USD
CY2013Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
548267000 USD
CY2014Q2 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
760756000 USD
CY2013Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
548322000 USD
CY2013 us-gaap Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Aggregate Losses
AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses
0 USD
us-gaap Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Aggregate Losses
AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses
0 USD
us-gaap Available For Sale Securities Continuous Unrealized Loss Position Aggregate Losses
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses
369000 USD
CY2013 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Aggregate Losses
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses
447000 USD
CY2014Q2 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
164180000 USD
CY2013Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
239812000 USD
CY2013 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Aggregate Losses
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses
447000 USD
us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Aggregate Losses
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses
369000 USD
CY2014Q2 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
164180000 USD
CY2013Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
239812000 USD
CY2014Q2 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
0 USD
CY2013Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
0 USD
CY2014Q2 us-gaap Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
4043000 USD
CY2013Q4 us-gaap Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
4138000 USD
CY2014Q2 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
538647000 USD
CY2013Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
383410000 USD
CY2014Q2 us-gaap Available For Sale Securities Debt Maturities After Ten Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue
1154000 USD
CY2013Q4 us-gaap Available For Sale Securities Debt Maturities After Ten Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue
1177000 USD
CY2014Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
216774000 USD
CY2013Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
158376000 USD
CY2014Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
760618000 USD
CY2013Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
547101000 USD
CY2014Q2 us-gaap Other Inventory Net Of Reserves
OtherInventoryNetOfReserves
27352000 USD
CY2013Q2 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
500000 USD
us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
500000 USD
CY2013Q2 us-gaap Available For Sale Securities Gross Realized Losses
AvailableForSaleSecuritiesGrossRealizedLosses
0 USD
us-gaap Available For Sale Securities Gross Realized Losses
AvailableForSaleSecuritiesGrossRealizedLosses
0 USD
CY2013 us-gaap Available For Sale Securities Gross Unrealized Gains
AvailableForSaleSecuritiesGrossUnrealizedGains
392000 USD
us-gaap Available For Sale Securities Gross Unrealized Gains
AvailableForSaleSecuritiesGrossUnrealizedGains
7205000 USD
us-gaap Available For Sale Securities Gross Unrealized Loss
AvailableForSaleSecuritiesGrossUnrealizedLoss
369000 USD
CY2013 us-gaap Available For Sale Securities Gross Unrealized Loss
AvailableForSaleSecuritiesGrossUnrealizedLoss
447000 USD
CY2013Q2 us-gaap Available For Sale Securities Income Tax Expense On Change In Unrealized Holding Gain Or Loss
AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss
0 USD
CY2014Q2 us-gaap Available For Sale Securities Income Tax Expense On Change In Unrealized Holding Gain Or Loss
AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss
1400000 USD
us-gaap Available For Sale Securities Income Tax Expense On Change In Unrealized Holding Gain Or Loss
AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss
0 USD
us-gaap Available For Sale Securities Income Tax Expense On Change In Unrealized Holding Gain Or Loss
AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss
1100000 USD
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
600135000 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
535608000 USD
CY2013Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
381675000 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
230276000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
64527000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
151399000 USD
CY2014Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
95533000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
183987000 USD
CY2013Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
85591000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
163629000 USD
CY2014Q2 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
282261000 USD
CY2013Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
320315000 USD
CY2014Q2 us-gaap Cost Of Goods Sold
CostOfGoodsSold
29945000 USD
us-gaap Cost Of Goods Sold
CostOfGoodsSold
55304000 USD
CY2013Q2 us-gaap Cost Of Goods Sold
CostOfGoodsSold
27283000 USD
us-gaap Cost Of Goods Sold
CostOfGoodsSold
57418000 USD
us-gaap Costs And Expenses
CostsAndExpenses
883095000 USD
CY2014Q2 us-gaap Costs And Expenses
CostsAndExpenses
443294000 USD
CY2013Q2 us-gaap Costs And Expenses
CostsAndExpenses
299539000 USD
us-gaap Costs And Expenses
CostsAndExpenses
586153000 USD
us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
521876 shares
CY2013Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
400000000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-32543000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
92522000 USD
us-gaap Deferred Revenue Additions
DeferredRevenueAdditions
25500000 USD
CY2014Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
54154000 USD
CY2013Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
34185000 USD
CY2013Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
107677000 USD
CY2014Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
128042000 USD
CY2013Q4 us-gaap Deferred Tax Assets Liabilities Net Current
DeferredTaxAssetsLiabilitiesNetCurrent
44677000 USD
CY2014Q2 us-gaap Deferred Tax Assets Liabilities Net Current
DeferredTaxAssetsLiabilitiesNetCurrent
37291000 USD
CY2014Q2 us-gaap Deferred Tax Assets Liabilities Net Noncurrent
DeferredTaxAssetsLiabilitiesNetNoncurrent
270367000 USD
CY2013Q4 us-gaap Deferred Tax Assets Liabilities Net Noncurrent
DeferredTaxAssetsLiabilitiesNetNoncurrent
231878000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
24546000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
19109000 USD
us-gaap Description Of New Accounting Pronouncements Not Yet Adopted
DescriptionOfNewAccountingPronouncementsNotYetAdopted
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Recently Issued Accounting Standards </font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued a new standard related to revenue recognition, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;">, which will replace existing revenue recognition guidance. The new standard requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. To achieve that core principle, an entity must identify the contract(s) with a customer, identify the performance obligations in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract, and recognize revenue when (or as) the entity satisfies the performance obligation. The new standard will be effective for annual and interim reporting periods beginning after December 15, 2016, and early adoption is not permitted. The standard allows for two transition methods - retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying the standard recognized at the date of initial adoption. The Company has not yet determined its method of transition and is evaluating the impact that this guidance will have on the Company's financial statements.</font></div></div>
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.91
CY2013Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.89
CY2014Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.92
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.58
CY2014Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.82
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.69
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.40
CY2013Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.79
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.357
CY2014Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.543
us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
244197000 USD
us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
7876000 USD
CY2013Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.408
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.582
us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.039
CY2014Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
51786000 USD
CY2013Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
69429000 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-10787000 USD
CY2014Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-10787000 USD
CY2013Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
CY2013Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
147692000 USD
CY2014Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
203119000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
289523000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
378382000 USD
CY2014Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
110384000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
220204000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
103273000 USD
CY2013Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
60316000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
16820000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
35592000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-61043000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
206149000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
39838000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-11579000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
31144000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
37295000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2700000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
29446000 USD
CY2013Q2 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
2645000 shares
CY2014Q2 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
2877000 shares
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
2337000 shares
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
3018000 shares
CY2013Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
10291000 shares
CY2014Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
9359000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
10296000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
9615000 shares
CY2014Q2 us-gaap Interest Expense
InterestExpense
10177000 USD
us-gaap Interest Expense
InterestExpense
23040000 USD
CY2013Q2 us-gaap Interest Expense
InterestExpense
11365000 USD
us-gaap Interest Expense
InterestExpense
21790000 USD
CY2013Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
14352000 USD
CY2014Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
12215000 USD
CY2013Q4 us-gaap Inventory Net
InventoryNet
70354000 USD
CY2014Q2 us-gaap Inventory Net
InventoryNet
109897000 USD
CY2013Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
9120000 USD
CY2014Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
10220000 USD
CY2013Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
35868000 USD
CY2014Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
60110000 USD
CY2014Q2 us-gaap Inventory Write Down
InventoryWriteDown
800000 USD
us-gaap Inventory Write Down
InventoryWriteDown
1900000 USD
CY2013Q2 us-gaap Inventory Write Down
InventoryWriteDown
1700000 USD
us-gaap Inventory Write Down
InventoryWriteDown
4900000 USD
us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
1410000 USD
CY2013Q2 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
954000 USD
us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
2614000 USD
CY2014Q2 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
1677000 USD
CY2014Q2 us-gaap Liabilities
Liabilities
1087236000 USD
CY2013Q4 us-gaap Liabilities
Liabilities
998937000 USD
CY2014Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3456078000 USD
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2951013000 USD
CY2014Q2 us-gaap Liabilities Current
LiabilitiesCurrent
351578000 USD
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
298835000 USD
CY2014Q2 us-gaap Licenses Revenue
LicensesRevenue
7788000 USD
us-gaap Licenses Revenue
LicensesRevenue
15330000 USD
CY2013Q2 us-gaap Licenses Revenue
LicensesRevenue
7116000 USD
us-gaap Licenses Revenue
LicensesRevenue
13860000 USD
CY2014Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
216774000 USD
CY2013Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
158376000 USD
CY2014Q2 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
550818000 USD
CY2013Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
389891000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
37564000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-31958000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-354354000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-31055000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
381317000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
214412000 USD
us-gaap Net Income Loss
NetIncomeLoss
158178000 USD
us-gaap Net Income Loss
NetIncomeLoss
186250000 USD
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
87376000 USD
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
92735000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-29963000 USD
CY2013Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-10411000 USD
CY2014Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-19287000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-21630000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
311153000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
408345000 USD
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
222406000 USD
CY2013Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
158103000 USD
CY2014Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
48537000 USD
CY2013Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
29022000 USD
CY2014Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
8877000 USD
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5327000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2263000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
5451000 USD
CY2013Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1785000 USD
CY2014Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
2798000 USD
CY2013Q4 us-gaap Other Inventory Net Of Reserves
OtherInventoryNetOfReserves
11014000 USD
CY2013Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
11330000 USD
CY2014Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
14968000 USD
us-gaap Other Noncash Expense
OtherNoncashExpense
10871000 USD
us-gaap Other Noncash Expense
OtherNoncashExpense
11315000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-6598000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-18323000 USD
us-gaap Payments For Repurchase Of Warrants
PaymentsForRepurchaseOfWarrants
0 USD
us-gaap Payments For Repurchase Of Warrants
PaymentsForRepurchaseOfWarrants
143041000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
73137000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
64990000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
374509000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
282643000 USD
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
135695000 USD
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
55656000 USD
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2014Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2014Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000 shares
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000 shares
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2014Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
60674000 USD
CY2013Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
32952000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
63057000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
34300000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
307244000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
155850000 USD
CY2014Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
707321000 USD
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
526983000 USD
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
0 USD
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
61125000 USD
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
997000 USD
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
534000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
367762000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
581880000 USD
CY2014Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
294501000 USD
CY2013Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
187463000 USD
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-92692000 USD
CY2014Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
65486000 USD
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
184802000 USD
CY2014Q2 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
142595000 USD
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
273103000 USD
CY2013Q2 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
85529000 USD
us-gaap Revenue Recognition Revenue Reductions
RevenueRecognitionRevenueReductions
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from product sales is recorded net of applicable provisions for rebates and chargebacks under governmental programs (including Medicaid), distribution-related fees, prompt pay discounts, and other sales-related deductions. </font></div></div>
us-gaap Revenues
Revenues
897306000 USD
CY2014Q2 us-gaap Revenues
Revenues
665700000 USD
CY2013Q2 us-gaap Revenues
Revenues
457642000 USD
us-gaap Revenues
Revenues
1291440000 USD
CY2013Q2 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
333893000 USD
CY2014Q2 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
418022000 USD
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
652633000 USD
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
780400000 USD
CY2013Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
72463000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
149723000 USD
CY2014Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
102414000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
211264000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
151920000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
97473000 USD
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
156368000 USD
us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
0 USD
us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
0 USD
us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
62117000 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
30498000 USD
CY2014Q2 us-gaap Stockholders Equity
StockholdersEquity
2368842000 USD
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
1952076000 USD
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
1245385000 USD
CY2013Q2 us-gaap Stockholders Equity
StockholdersEquity
1493337000 USD
CY2014Q2 us-gaap Treasury Stock Shares
TreasuryStockShares
521876 shares
CY2013Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
0 shares
us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
521876 shares
CY2014Q2 us-gaap Treasury Stock Value
TreasuryStockValue
-43848000 USD
CY2013Q4 us-gaap Treasury Stock Value
TreasuryStockValue
0 USD
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
0 USD
CY2014Q2 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
25082000 USD
CY2013Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
24601000 USD
us-gaap Valuation Allowances And Reserves Charged To Other Accounts
ValuationAllowancesAndReservesChargedToOtherAccounts
51841000 USD
us-gaap Valuation Allowances And Reserves Deductions
ValuationAllowancesAndReservesDeductions
51360000 USD
CY2013Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
13360000 shares
CY2014Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
12641000 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
13036000 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
13016000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
113121000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
110305000 shares
CY2013Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
111060000 shares
CY2014Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
113032000 shares
CY2014Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
100391000 shares
CY2013Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
97700000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
97289000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
100085000 shares
CY2013Q4 regn Accrued Capital Expenditures
AccruedCapitalExpenditures
16100000 USD
CY2014Q2 regn Accrued Capital Expenditures
AccruedCapitalExpenditures
35100000 USD
CY2013Q2 regn Accrued Capital Expenditures
AccruedCapitalExpenditures
8100000 USD
CY2012Q4 regn Accrued Capital Expenditures
AccruedCapitalExpenditures
8600000 USD
CY2014Q2 regn Accrued Clinical Trial Expense Current
AccruedClinicalTrialExpenseCurrent
35498000 USD
CY2013Q4 regn Accrued Clinical Trial Expense Current
AccruedClinicalTrialExpenseCurrent
23654000 USD
CY2013Q4 regn Accruedsalesrelatedchargesdeductionsandroyalties
Accruedsalesrelatedchargesdeductionsandroyalties
66855000 USD
CY2014Q2 regn Accruedsalesrelatedchargesdeductionsandroyalties
Accruedsalesrelatedchargesdeductionsandroyalties
100333000 USD
regn Amountofnonrefundablepaymentreceivedforcollaborationagreement
Amountofnonrefundablepaymentreceivedforcollaborationagreement
25500000 USD
regn Costofmanufacturing
Costofmanufacturing
32533000 USD
CY2013Q2 regn Costofmanufacturing
Costofmanufacturing
12330000 USD
CY2014Q2 regn Costofmanufacturing
Costofmanufacturing
16434000 USD
regn Costofmanufacturing
Costofmanufacturing
13364000 USD
regn Debt Conversion
DebtConversion
61100000 USD
CY2014Q2 regn Deferred Revenue From Related Party Current
DeferredRevenueFromRelatedPartyCurrent
12979000 USD
CY2013Q4 regn Deferred Revenue From Related Party Current
DeferredRevenueFromRelatedPartyCurrent
12815000 USD
CY2014Q2 regn Deferred Revenue From Related Party Noncurrent
DeferredRevenueFromRelatedPartyNoncurrent
75862000 USD
CY2013Q4 regn Deferred Revenue From Related Party Noncurrent
DeferredRevenueFromRelatedPartyNoncurrent
76522000 USD
CY2013Q4 regn Facility Lease Obligations Current
FacilityLeaseObligationsCurrent
939000 USD
CY2014Q2 regn Facility Lease Obligations Current
FacilityLeaseObligationsCurrent
1060000 USD
CY2013Q4 regn Facility Lease Obligations Noncurrent
FacilityLeaseObligationsNoncurrent
184258000 USD
CY2014Q2 regn Facility Lease Obligations Noncurrent
FacilityLeaseObligationsNoncurrent
234525000 USD
regn Facilityleaseobligationrecognizedduringtheperiod
Facilityleaseobligationrecognizedduringtheperiod
4700000 USD
regn Facilityleaseobligationrecognizedduringtheperiod
Facilityleaseobligationrecognizedduringtheperiod
50600000 USD
CY2013Q2 regn Incremental Common Shares Attributable To Nonvested Restricted Shares
IncrementalCommonSharesAttributableToNonvestedRestrictedShares
424000 shares
CY2014Q2 regn Incremental Common Shares Attributable To Nonvested Restricted Shares
IncrementalCommonSharesAttributableToNonvestedRestrictedShares
405000 shares
regn Incremental Common Shares Attributable To Nonvested Restricted Shares
IncrementalCommonSharesAttributableToNonvestedRestrictedShares
403000 shares
regn Incremental Common Shares Attributable To Nonvested Restricted Shares
IncrementalCommonSharesAttributableToNonvestedRestrictedShares
383000 shares
regn Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentsmaybereceived200million
Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentsmaybereceived200million
200000000 USD
CY2014Q1 regn Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswerereceived
Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswerereceived
500000000 USD
CY2014Q1 regn Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswerereceived600million
Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswerereceived600million
600000000 USD
CY2014Q2 regn Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswerereceived700million
Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswerereceived700million
700000000 USD
regn Levelsoftwelvemonthssalesatwhichsalesmilestonepaymentsmaybereceived1billion
Levelsoftwelvemonthssalesatwhichsalesmilestonepaymentsmaybereceived1billion
1000000000 USD
CY2014Q1 regn Maximumnumberofsharesissuableuponexerciseofwarrants
Maximumnumberofsharesissuableuponexerciseofwarrants
4760840 shares
CY2014Q2 regn Maximumnumberofsharesissuableuponexerciseofwarrants
Maximumnumberofsharesissuableuponexerciseofwarrants
4033324 shares
CY2014Q2 regn Numberofsalesmilestonepaymentsthe Companyreceived
NumberofsalesmilestonepaymentstheCompanyreceived
1
CY2014Q1 regn Numberofsalesmilestonepaymentsthe Companyreceived
NumberofsalesmilestonepaymentstheCompanyreceived
2
regn Other Collaboration Revenue
OtherCollaborationRevenue
46011000 USD
regn Other Collaboration Revenue
OtherCollaborationRevenue
222607000 USD
CY2014Q2 regn Other Collaboration Revenue
OtherCollaborationRevenue
97295000 USD
CY2013Q2 regn Other Collaboration Revenue
OtherCollaborationRevenue
31104000 USD
regn Period For Achieving Sales Target For Milestone Payment Rolling Basis
PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis
P12M
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
dei Document Period End Date
DocumentPeriodEndDate
2014-06-30
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0000872589
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Registrant Name
EntityRegistrantName
REGENERON PHARMACEUTICALS INC

Files In Submission

Name View Source Status
0001532176-14-000035-index-headers.html Edgar Link pending
0001532176-14-000035-index.html Edgar Link pending
0001532176-14-000035.txt Edgar Link pending
0001532176-14-000035-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
regn-063014x10q.htm Edgar Link pending
regn-20140630.xml Edgar Link completed
regn-20140630.xsd Edgar Link pending
regn-20140630_cal.xml Edgar Link unprocessable
regn-20140630_def.xml Edgar Link unprocessable
regn-20140630_lab.xml Edgar Link unprocessable
regn-20140630_pre.xml Edgar Link unprocessable
regn-ex_106xamendemntxciti.htm Edgar Link pending
regn-ex_107xamendmentxcred.htm Edgar Link pending
regn-ex_108xamendmentxgold.htm Edgar Link pending
regn-ex_109xamendmentxmorg.htm Edgar Link pending
regn-ex_311x06302014x10q.htm Edgar Link pending
regn-ex_312x06302014x10q.htm Edgar Link pending
regn-ex_32x06302014x10q.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending